Chigene (Beijing) Translational Medical Research Center Co. Ltd. (previous known as JOY ORIENTAL Co.) is a leading company in precision medicine in China. By applying state-of-the art customizable NGS technology on human genome, we focus our research and products on tumor mutation profiling and neoantigen applications to provide personalized immuno-therapies for cancer patients.
Chigene has a complete product line to provide a "one-stop" solution for precision medicine, covering highly integrated sequencing solution for diagnosis, prevention, and management of Mendelian inheritance disease, birth-defects, tumors, chronic diseases, pharmacogenomics, and other health care practices.
Chigene has built the world's largest database of genotype-phenotype associated genetic diseases for the Chinese population, and developed the world’s first genetic diagnostic platform based on the big data analysis of human genome.
Chigene has developed a full spectrum of NGS based sequencing products for tumor therapeutics. Along with the sister company Chineo, we perfected the neoantigen technology to offer personalized immuno-therapies for cancer treatment, through which we achieved a closed-loop solution for cancer diagnosis and treatment.
We are the first company in industry, who established the methodology to measure enzyme activity of mitochondrial and lysosomal.
We are the first company in industry, who established the methodology to sequence and diagnosis 4000 Mendelian inheritance disease based on Sanger PCR; For each of the disease, the correlated gene's specific primers were designed.
We are the first company in industry, who established the methodology to sequence and diagnosis 4000 Mendelian inheritance disease based on NGS; Same testing package has been found that was launched in US. market in 2015, which is called "clinical based exome genomic sequencing".
We are the first one in industry, who advocates NGS based genetic analysis should be based on "Three Elements": "Biological impact+ Genetic inheritance pattern+ Clinical features"
We are the first one in industry, who applied "the five grading system" for a genetic variant analysis, which is two years ahead of ACMG.
We are the first company in industry, who advocates Trio based NGS test, while the others were still using "Proband" as a standard testing mode.
Chigene has been dedicating to build the world's largest database of genotype-phenotype associated genetic diseases for the Chinese population, and Chigene has accumulated nearly hundred thousand WES based genomic data.
Chigene has been devoting to develop the world's first genetic diagnostic platform based on the big data analysis of human genome.
We have been collaborating with more than 100 hospitals national wide, and working along with them towards the goal of building big data based medical diagnostic platform.
We also have been collaborating with national medical associations, and the goal for us is to keep working on building the genetic diagnostic platform based on the Chinese population.
Based on our Chigene's genotype-phenotype associated genetic diseases database and genetic diagnostic platform, through applying NGS based Trio whole exome sequencing (WES), Trio (WES+ hot spots in none-coding area +CNVseq), Sub whole genome sequencing (WGS)+RNAseq, we can achieve diagnosis 5000 genetic diseases at once.
The first stage (Pre-pregnant): Screening total of 1803 recessive genetic diseases associated genes for a couple at the stage of pre-pregnant or at the early stage of pregnant.
The second stage (Prenatal): By applying WES+CNVseq, sequencing genes which related to a total of 5000 genetic diseases for a baby right before birth. Provide genetic consulting for the couple when needed.
The third stage (After birth): By applying WES+CNVseq, sequencing genes which related to a total of 5000 genetic diseases for a child after birth. Provide medical treatment and genetic consulting when needed.
Integrated full spectrum of NGS based sequencing, along with neoantigen based personalized immuno-therapies for cancer treatment, we achieved a closed-loop solution for cancer diagnosis and treatment.
For solid tumors, results obtained from full spectrum screening can be utilized for neoantigen based personalized immuno-therapies of cancer treatment, which serves as a powerful tool to prevent disease recurrence for stage II/III patients after surgery, and a reverse treatment for stage IV cancer patients.
For blood tumors, results obtained from full spectrum screening can be utilized directly to guide CD19/20 &BCMA CAR-T T/B tumors neoantigen therapy.
We also have product lines, covering chronic diseases, such as: hypertension and diabetes; pharmacogenomics, and other health care practices related precision medicine that would be highly integrated with sequencing technologies.
Big Data Analysis
24 hours, 365 days non-stop data computing service, thousands of WES data running daily, PB level Chinese human genome based big data analysis & storage system.
Chigene Genetic Diagnostic Platform
AI analysis platform: through online diagnostic platform, we build up data transparency for each sample, such as: QC data, Variants annotation logics, the degrees of match between detected variants and genetic diseases (genotype to phenotype), ACMG pathogenic grading, and the prediction of different algorithms tools/databases, etc.
We dedicate to build the world's largest database of genotype-phenotype associated genetic diseases based on Chinese human genome, which includes the phenotypes of 7000 genetic diseases, genes and variants information.
We have been developing the world's largest database of genotype-phenotype associated genetic diseases based on 100,000 Chinese population, which provides the most powerful analysis tool for genetic disease diagnosis.
HONOR & QUALIFICATION
Medical Laboratory Qualification
Quality Evaluation Between Laboratories
Quality Evaluation Between Laboratories